Prognostic potential of DNA methylation and transcript levels of HIF1A and EPAS1 in colorectal cancer

Molecular Cancer Research

Volumn 12, Issue 8, 2014, Pages 1112-1127

  Rawłuszko Wieczorek, Agnieszka Anna ^a   Horbacka, Karolina ^a   Krokowicz, Piotr ^a   Misztal, Matthew ^a   Jagodziński, Paweł Piotr ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; DNA METHYLTRANSFERASE INHIBITOR; ENDOTHELIALPAS DOMAIN CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA ISOLATION; DNA METHYLATION; DNA SEQUENCE; FEMALE; FOLLOW UP; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANOXIA; COLORECTAL TUMOR; GENETICS; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROGNOSIS; RNA, MESSENGER;

EID: 84905980742     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0054     Document Type: Article

References (48)

1. Webb JD, Coleman ML, Pugh CW. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 2009;66:3539-54.
2. Jokilehto T, Jaakkola PM. The role of HIF prolyl hydroxylases in tumour growth. J Cell Mol Med 2010;14:758-70.
3. Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, et al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 2009;100:1666-73.
4. Schmitz KJ, Muller CI, Reis H, Alakus H, Winde G, Baba HA, et al. Combined analysis of hypoxia-inducible factor 1 alpha and metallothionein indicates an aggressive subtype of colorectal carcinoma. Int J Colorectal Dis 2009;24:1287-96.
5. Rajaganeshan R, Prasad R, Guillou PJ, Scott N, Poston G, Jayne DG. Expression patterns of hypoxic markers at the invasive margin of colorectal cancers and liver metastases. Eur J Surg Oncol 2009;35:1286-94.
6. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004;10:8554-60. (Pubitemid 40053424)
7. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, et al. Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003;105:176-81. (Pubitemid 36505317)
8. Furlan D, Sahnane N, Carnevali I, Cerutti R, Bertoni F, Kwee I, et al. Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 2008;39:1483-94.
9. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, et al. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010;176:2292-301.
10. Imamura T, Kikuchi H, Herraiz MT, Park DY, Mizukami Y, Mino- Kenduson M, et al. HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer 2009;124:763-71.
11. Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 2008;10:674-9. (Pubitemid 351883883)
12. Ma J, Zhang L, Ru GQ, Zhao ZS, Xu WJ. Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma. World J Gastroenterol 2007;13:1680-6. (Pubitemid 46711338)
13. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010;29:181-206.
14. Koslowski M, Luxemburger U, Tureci O, Sahin U. Tumor-associated CpG demethylation augments hypoxia-induced effects by positive autoregulation of HIF-1alpha. Oncogene 2011;30:876-82.
15. CpGPlot/CpGReport/Isochore. Available from: http://www.ebi.ac.uk/Tools/ seqstats/emboss-cpgplot/
16. CpG Island Searcher. Available from: http://cpgislands.usc.edu/
17. UCSC Genome Bioinformatics Site. Available from: http://genome.ucsc.edu/
18. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics (Oxford, England) 2005;21:4067-8. (Pubitemid 41631851)
19. Rohde C, Zhang Y, Jurkowski TP, Stamerjohanns H, Reinhardt R, Jeltsch A. Bisul fite sequencing Data Presentation and Compilation (BDPC) web server-a useful tool for DNA methylation analysis. Nucleic Acids Res 2008;36:e34.
20. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007;35:e41.
21. Rawluszko AA, Horbacka K, Krokowicz P, Jagodzinski PP. Decreased expression of 17-beta-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon. BMC Cancer 2011;11:522.
22. Hsieh CL. Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 1994;14:5487-94.
23. Shao Y, Zhang W, Zhang C, Wu Q, Yang H, Zhang J, et al. Highresolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer Invest 2010;28:642-8.
24. Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES. A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. BMC Cancer 2012;12:486.
25. Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp- Demtroder K, et al. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011;129:2855-66.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidiniumthiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9. (Pubitemid 17064313)
27. Rawluszko AA, Bujnicka KE, Horbacka K, Krokowicz P, Jagodzi Ski PP. Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer 2013;13:526.
28. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
29. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 2001;92:165- 71.
30. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8. (Pubitemid 32708633)
31. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev 2012;12: 9-22.
32. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
33. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, et al. Expression of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma. Cancer Sci 2005;96:176-82. (Pubitemid 40575919)
34. Luczak MW, Roszak A, Pawlik P, Kedzia H, Lianeri M, Jagodzinski PP. Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol Rep 2011;26:1259- 64.
35. Minet E, Ernest I, Michel G, Roland I, Remacle J, Raes M, et al. HIF1A gene transcription is dependent on a core promoter sequence encompassing activating and inhibiting sequences located upstream from the transcription initiation site and cis elements located within the 5′UTR. Biochem Biophys Res Commun 1999;261:534-40. (Pubitemid 29392511)
36. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005;37:535-40. (Pubitemid 40022930)
37. Galban S, Kuwano Y, Pullmann RJr, Martindale JL, Kim HH, Lal A, et al. RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2008;28:93-107.
38. Mohammed N, Rodriguez M, Garcia V, Garcia JM, Dominguez G, Pena C, et al. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncol Lett 2011;2:719-24.
39. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, et al. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A 2010;107:14182-7.
40. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74. (Pubitemid 37499822)
41. Hu CJ, Sataur A, Wang L, Chen H, Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Mol Biol Cell 2007;18: 4528-42. (Pubitemid 350060179)
42. Lau KW, Tian YM, Raval RR, Ratcliffe PJ, Pugh CW. Target gene selectivity of hypoxia-inducible factor-alpha in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br J Cancer 2007;96: 1284-92. (Pubitemid 46625064)
43. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006;66:6264-70.
44. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005;8:131-41. (Pubitemid 41132742)
45. Walczak-Drzewiecka A, Ratajewski M, Pulaski L, Dastych J. DNA methylation-dependent suppression of HIF1A in an immature hematopoietic cell line HMC-1. Biochem Biophys Res Commun 2010;391: 1028-32.
46. Migliore L, Migheli F, Spisni R, Coppede F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011;2011: 792362.
47. Momparler RL. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 2005;42(3 Suppl 2):S9-16.
48. Ghoshal K, Motiwala T, Claus R, Yan P, Kutay H, Datta J, et al. HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PloS ONE 2010;5:e10338.